AIM ImmunoTech Inc
AIM
查看详细走势图
1.440USD
+0.079+5.83%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.98M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.83%
5天
+5.11%
1月
+8.27%
6月
-82.65%
今年开始到现在
0.00%
1年
0.00%
查看详细走势图
TradingKey AIM ImmunoTech Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
AIM ImmunoTech Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名138/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价22.00。中期看，股价处于下降通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
AIM ImmunoTech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
22.000
目标均价
+1347.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
AIM ImmunoTech Inc亮点
亮点风险
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
业绩高增长
公司营业收入稳步增长，连续3年增长20.57%
业绩增长期
公司处于发展阶段，最新年度总收入170.00K美元
估值高估
公司最新PE估值-0.08，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
AIM ImmunoTech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
AIM ImmunoTech Inc简介
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
公司代码AIM
公司AIM ImmunoTech Inc
CEOEquels (Thomas K)
网址https://aimimmuno.com/
常见问题
AIM ImmunoTech Inc(AIM)的当前股价是多少？
AIM ImmunoTech Inc(AIM)的当前股价是 1.440。
AIM ImmunoTech Inc的股票代码是什么？
AIM ImmunoTech Inc的股票代码是AIM。
AIM ImmunoTech Inc股票的52周最高点是多少？
AIM ImmunoTech Inc股票的52周最高点是36.000。
AIM ImmunoTech Inc股票的52周最低点是多少？
AIM ImmunoTech Inc股票的52周最低点是1.260。
AIM ImmunoTech Inc的市值是多少？
AIM ImmunoTech Inc的市值是3.98M。
AIM ImmunoTech Inc的净利润是多少？
AIM ImmunoTech Inc的净利润为-17.32M。
现在AIM ImmunoTech Inc(AIM)的股票是买入、持有还是卖出？
根据分析师评级，AIM ImmunoTech Inc(AIM)的总体评级为买入，目标价格为22.000。
AIM ImmunoTech Inc(AIM)股票的每股收益（EPS TTM）是多少
AIM ImmunoTech Inc(AIM)股票的每股收益（EPS TTM）是-17.823。
相关品种
